文献速递胃肠动力与功能性疾病

荟萃分析:功能性消化不良的安慰剂反应及其决定因素

Meta-Analysis: Placebo Response and Its Determinants in Functional Dyspepsia.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

该荟萃分析纳入58项双盲随机对照试验,共17,890例功能性消化不良患者,其中6,732例接受安慰剂。症状改善和完全缓解的合并安慰剂反应率分别为44.3%和15.6%。评估≥8周时安慰剂反应率较低;评估完全症状缓解的试验即使短于8周也显示较低的安慰剂反应率。

要点

  • 功能性消化不良试验中安慰剂反应率因疗效标准而异。
  • 症状改善的合并安慰剂反应率为44.3%,完全缓解为15.6%。
  • 评估完全症状缓解的短程试验安慰剂反应率稳定且较低。

核心结论

  • 功能性消化不良双盲随机对照试验的合并安慰剂反应率取决于疗效标准。
  • 评估完全症状缓解的试验在短期试验中显示稳定低安慰剂反应率。

研究设计与样本

  • 系统检索PubMed、EMBASE和Cochrane Central Register of Controlled Trials,纳入比较药物与安慰剂的双盲随机对照试验。
  • 共纳入58项符合标准的安慰剂对照随机对照试验,来自52篇选定文献,17,890例参与者中6,732例接受安慰剂。
  • 症状改善和完全缓解分别作为独立主要终点分析,随机化后任何原因的脱落假定为治疗失败。
  • 采用随机效应模型合并安慰剂反应率,并评估试验特征对安慰剂反应幅度的影响。

主要发现

  • 症状改善的合并安慰剂反应率为44.3%。
  • 完全缓解的合并安慰剂反应率为15.6%。
  • 当评估改善≥8周时,安慰剂反应率较低。
  • 评估完全症状缓解的试验即使短于8周也显示较低的安慰剂反应率。

关键数值与推荐

  • 症状改善合并安慰剂反应率44.3%。
  • 完全缓解合并安慰剂反应率15.6%。
  • 评估改善≥8周时安慰剂反应率较低。
  • 评估完全症状缓解的试验即使<8周也显示较低安慰剂反应率。

临床怎么用

  • 在功能性消化不良药物开发中,应考虑安慰剂反应率受疗效评估标准影响。
  • 选择完全症状缓解作为终点可能有助于降低短期试验中的安慰剂反应率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Placebo response rates are relatively higher in clinical trials of disorders of brain-gut interaction. However, placebo response in functional dyspepsia (FD) has not been well described. Minimizing placebo response is important in drug development. We therefore conducted a meta-analysis to determine placebo response in trials for FD and to identify factors affecting placebo response rates. METHODS: PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were searched to identify double-blinded randomized controlled trials (RCTs) comparing medication with placebo in patients with FD. Both symptom improvement and complete relief were considered as separate primary endpoints in the analysis. Proportions of placebo patients experiencing any symptom improvement or complete relief were calculated. Dropouts after randomization for any reason were assumed to represent treatment failure for data extraction and analysis. Placebo response was pooled by a random-effects model, and effects of trial characteristics on the magnitude of placebo response were evaluated. RESULTS: In 58 eligible placebo-controlled RCTs of FD from 52 selected citations, 6,732 of 17,890 participants in all trials received placebo. Pooled placebo response rates for symptom improvement and complete relief were 44.3% and 15.6%, respectively. The placebo response rate was lower when improvements were assessed for ≥8 weeks. Trials assessing complete symptom relief showed lower placebo response rates even in trials for <8 weeks. DISCUSSION: Our systematic review and meta-analysis showed that pooled placebo response rates in double-blinded RCTs of FD depended on efficacy criteria. Trials assessing complete symptom relief showed stable low placebo response rates in short-term trials.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Huang X, Oshima T, Tomita T, et al. Meta-Analysis: Placebo Response and Its Determinants in Functional Dyspepsia. Am J Gastroenterol. 2021. PMID: 34404084. doi:10.14309/ajg.0000000000001397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。